Is BPC-157 Legal? Its US Regulatory Status After the HHS Policy (November 2026)

Is BPC-157 legal in the US?

It depends on the channel. BPC-157 is not an FDA-approved drug, and it is not on FDA’s 503A bulks list (FDA). Since 30 October 2026, though, an HHS enforcement discretion policy says HHS does not intend to act against 503A compounders (state-licensed pharmacies, federal facilities and licensed physicians) that compound BPC-157 acetate on a valid prescription for subcutaneous, intramuscular, oral or topical use, if all ten of the policy’s conditions are met (HHS policy).

Outside that channel, nothing has changed. FDA can still treat BPC-157 sold as a “research chemical” as an unapproved new drug when the seller’s site shows it is intended for human use (FDA warning letter 733652). State law and sports anti-doping rules apply on top.

What is BPC-157, chemically?

BPC-157 is a synthetic 15-amino-acid peptide. HHS’s Appendix B defines the covered substance as BPC-157 acetate, with the sequence H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH, molecular formula C₆₂H₉₈N₁₆O₂₂·xCH₃COOH and molecular weight 1419.54 + x(60.05) g/mol (HHS Appendix B).

The salt form matters. The policy names the acetate, so a product made from a different salt, such as a TFA salt left over from synthesis, does not match the identity HHS defined. Identity, purity and counter-ion testing are explained in what the HHS testing standard asks a COA to show.

What is BPC-157’s regulatory timeline?

FDA’s category 2 page still carries its safety statement on BPC-157: compounded drugs containing it “may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization”. FDA says it has “no, or only limited, safety-related information for the proposed routes of administration” (FDA).

Why did HHS include BPC-157 when FDA staff advised against it?

Appendix B gives three reasons, in HHS’s words a “threefold” justification (HHS Appendix B):

1. “Historical use is now documented and quantified”, and HHS refers to “multiple human studies”.
2. The characterisation record now includes “a lot-specific certificate from an FDA-registered facility reporting the identity, impurity, endotoxin, microbial, and residual solvent results CDER found lacking”.
3. The policy’s conditions (lot-level testing, single-API products and MedWatch reporting) are meant to address the remaining risks.

These are HHS’s reasons for an enforcement decision. They are not an FDA finding of safety or effectiveness, and HHS repeats that compounded drugs are not FDA-approved. This page makes no health claims about BPC-157.

What conditions apply to compounded BPC-157?

All ten conditions, and who they apply to, are covered in HHS’s peptide compounding policy explained. This page does not give dosing or administration information.

What about research-use-only BPC-157?

Its position has not improved. HHS describes the policy as a way to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers” (HHS policy). FDA’s August 2026 warning letters treated RUO labelling as outweighed by human-use evidence on a seller’s site, including dosing calculators and bacteriostatic water bundles (FDA). The differences between the channels are set out in RUO vs compounded vs FDA-approved peptides.

Is BPC-157 banned in sport?

Yes. USADA’s athlete advisory for the 2027 WADA Prohibited List lists BPC-157 as “Prohibited under S0”, the class for non-approved substances (USADA). Sport Integrity Australia describes S0 substances as “prohibited at all times” (Sport Integrity Australia). The HHS policy has no effect on anti-doping rules. A prescription does not make BPC-157 permitted in competition or out of it.

What could change BPC-157’s status next?

Four things to watch, in roughly the order they could happen:

1. Comment-driven revisions. Comments on docket HHS-OASH-2026-0496 close on 13 November 2026. The Federal Register notice calls the document a draft and points readers to the HHS website for the most current version (notice). Routes, conditions or the testing standard could change.
2. A safety or quality signal. HHS says it may revisit the policy “in whole or in part” if a safety signal or product-quality issue arises with a compounded product in scope. That is what the MedWatch reporting condition is for (HHS policy).
3. A proposed rule. Adding BPC-157 to the 503A bulks list requires notice-and-comment rulemaking. HHS says FDA’s future rulemaking “may propose adding some or all of these peptides”. Holland & Knight noted that FDA’s 2016 proposed rule on ten bulk substances was not finalised until 2019 (Holland & Knight).
4. Political and legal change. Holland & Knight also wrote that enforcement discretion can be reversed quickly by a future administration, and that a rule departing from FDA staff findings could face challenge (Holland & Knight).

We log each of these on the peptide regulatory tracker with the date we last checked the primary record.

Does the policy change how BPC-157 can be advertised or paid for?

Not by itself. Advertising platforms and payment processors apply their own policies on unapproved substances, prescription drugs and research chemicals. A US enforcement policy is not product approval, and none of those platforms has to follow it. Telehealth providers offering compounded BPC-157 still face healthcare-advertising rules and certification requirements. Research-use sellers face the same restrictions as before. The background is in Google’s Unapproved Substances policy and peptides and payment processing for peptide companies. Check each platform’s current policy page before relying on either article, because these policies change.

Does the HHS policy apply outside the US?

No. It is a US federal enforcement policy. Other countries regulate BPC-157 under their own medicines and import rules, and those are not covered here. Our regulatory tracker currently covers US federal actions only. Region pages in our supplier directory show where listed suppliers say they ship.

Sources

• HHS Enforcement Discretion Policy, Appendices A and B (PDF as reposted by Reason; hhs.gov blocked automated access)
• Federal Register, FR Doc. 2026-22192, 30 October 2026 · docket HHS-OASH-2026-0496
• FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · FDA, 503A bulks page
• Holland & Knight, 16 October 2026 (PCAC votes and FDA staff briefing)
• FDA warning letter 733652, 24 August 2026
• USADA, 2027 Prohibited List advisory, 6 October 2026 · Sport Integrity Australia, BPC-157

Checked 4 November 2026. This page describes regulatory status only. It is not medical or legal advice and does not suggest that BPC-157 is safe or effective.

Frequently asked